Evonile Pharma Limited (NSE:EVONILE)

Market Cap	45.96B +123.9%
Revenue (ttm)	3.36B -6.2%
Net Income	-39.90M
EPS	-1.62
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123,088
Open	1,838.30
Previous Close	1,819.00
Day's Range	1,800.00 - 1,919.00
52-Week Range	950.00 - 2,588.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 3, 2026

About Evonile Pharma

Evonile Pharma Limited is involved in the pharmaceutical business in India and internationally. It operates Pharma International (Commercial operations), Development (Drug development), Biomedical Research, and Operations. The company offers therapeutic products in the areas of bone and pain under the Voveran brand; transplantation immunology under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. The company was incorporated in 1947 and is based in Mumbai,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1947
• Employees: 57
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: EVONILE

Financial Performance

In fiscal year 2026, Evonile Pharma's revenue was 3.54 billion, a decrease of -0.54% compared to the previous year's 3.56 billion. Earnings were 931.80 million, a decrease of -7.65%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 11, 2026

Data Sources Report a data error